NexMR aims to deliver fully characterized hits to support drug discovery pipelines.
Thanks to our proprietary technology using sensitivity-enhanced NMR we can screen libraries of thousands of molecules within days. We are also able to characterize the hits without idle time, as our technology encompasses affinity and structure determination.
Contrary to state-of-the-art methods (X-ray crystallography, surface plasmon resonance), we only require minimal assay development, allowing us to screen challenging targets which were not addressed so far.
The sample conditions used in NMR are milder and closer to physiological conditions than for other techniques, therefore facilitating the transition to further development.
Location: Switzerland, Zurich
Employees: 1-10
Investors 1
| Date | Name | Website |
| - | Venture Ki... | venturekic... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 25.01.2024 | ZKB Pionierpreis Technopark shortlists 11 startups | The Pionierpreis is an initiative by Zürcher Kantonalbank and Technopark Zürich and has been runnin... | startuptic... |
| 23.12.2022 | NexMR secures funds to accelerate drug discovery | startuptic... | |
| 15.06.2022 | CHF 40,000 for a NMR-based fragment screening platform and m... | NexMR: NMR-based fragment screening made easy Fragment-based drug design(FBDD) successfully brought ... | venturekic... |
| 30.03.2022 | Startups developing microwave passive devices, a NMR-based f... | MinWave Technologies: Microwave passive devices 10x smaller, 10x lighter Passive RF devices are part... | venturekic... |